Printer Friendly
The Free Library
19,585,952 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

BioTime Commences Rights Offer.


BERKELEY, Calif.--(BW HealthWire)--Feb. 12, 1999--BioTime, Inc. (Nasdaq:BTIM) announced that it commenced its rights offer under which it will offer 501,654 common shares to its shareholders.

Shareholders will receive one right for each share owned. The rights entitle en·ti·tle  
tr.v. en·ti·tled, en·ti·tling, en·ti·tles
1. To give a name or title to.

2. To furnish with a right or claim to something:
 the holders to purchase one common share for every 20 rights owned at a subscription price of $9.75 per share.

Shareholders who exercise all of their rights in full will be entitled en·ti·tle  
tr.v. en·ti·tled, en·ti·tling, en·ti·tles
1. To give a name or title to.

2. To furnish with a right or claim to something:
 to the additional privilege of subscribing for and purchasing any common shares left over by rights holders who fail to exercise their rights, plus up to 250,000 shares to cover over-subscriptions, subject to certain limitations and subject to allocation.

The rights offer will expire at 5:00 p.m. New York New York, state, United States
New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of
 time on March 9, 1999. The record date for determining BioTime shareholders entitled to receive the rights is Jan. 5, 1999.

The rights are transferable and have been approved for trading on the Nasdaq SmallCap Market under the symbol BTIMR beginning on Feb. 17, 1999. BioTime common shares will begin to trade ex-dividend on Feb. 16, 1999.0

BioTime, headquartered in Berkeley, Calif., is engaged in the research and development of blood plasma blood plasma
n.
The yellow or gray-yellow, protein-containing fluid portion of blood in which the blood cells and platelets are normally suspended.
 volume expanders, blood replacement solutions during hypothermic hy·po·ther·mi·a  
n.
Abnormally low body temperature.



[hypo- + Greek therm
 (low temperature) surgery, organ preservation solutions and technology for use in surgery, emergency trauma treatment, the preservation of organs awaiting transplant transplant
 or graft

Partial or complete organ or other body part removed from one site and attached at another. It may come from the same or a different person or an animal. One from the same person—most often a skin graft—is not rejected.
, and other applications.
COPYRIGHT 1999 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Feb 12, 1999
Words:230
Previous Article:Cheniere Receives Seismic Option Notice.
Next Article:H.D. Vest Inc. Announces First Quarter Results.
Topics:



Related Articles
BioTime Files for Rights Offering.
BioTime Raises Over $7.3 Million in Rights Offer; Announces That Rights Offer was Heavily Over-Subscribed.
BioTime Announces Allocation of Over-Subscription Shares Sold in Rights Offer.
Hextend Sales Begin, BioTime Receives Milestone Payments.
TERRA COMMENCES $2 BILLION RIGHTS OFFERING.
Organon Teknika and BioTime Announce Exclusive License Agreement for Hextend.
BioTime to Seek New International Marketing Partner.
Gateway offers a 'cooler' computer.
New desktops and flat panel LCDs.
E-series desktops: Gateway, Inc.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles